Research programme: melanocortin-4 receptor agonists - Amgen
Latest Information Update: 09 Sep 2008
At a glance
- Originator Amgen
- Class Amides; Piperazines
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 13 Sep 2004 Preclinical trials in Obesity in USA (PO)